Login to Your Account


BEGINNING TO NORMALIZE

After a slow start to the year, IPO activity for biotech companies picked up with 11 graduating to the public arena. However, the total amount raised was lower than the first quarter haul.

more »

Our Habitat for All Things Science
Monitoring, surveillance, cutting inappropriate use can slow brewing crisis

As its genesis so potently illustrates, the rise of antimicrobial resistance (AMR) will not be defused by an antibiotics arms race against the superbug.

Yes, new antibiotics form part of the answer, but work is needed in other areas and sectors to ensure the effectiveness of existing and novel drugs is maintained.

With resistant bacteria emerging in humans, animals and the environment – and spreading from one compartment to another – there is no geographical frontier or human/animal barrier.

READ MORE »

Opinion


Partners in Focus